Home
Categories
EXPLORE
History
Society & Culture
True Crime
Comedy
Health & Fitness
Sports
Business
About Us
Contact Us
Copyright
© 2024 PodJoint
Loading...
0:00 / 0:00
Podjoint Logo
ES
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/64/33/ba/6433ba0f-405d-81e6-bc82-4d4f04775f0a/mza_2622887070788468434.jpg/600x600bb.jpg
In the Interim...
Berry
24 episodes
1 week ago
A podcast on statistical science and clinical trials. Explore the intricacies of Bayesian statistics and adaptive clinical trials. Uncover methods that push beyond conventional paradigms, ushering in data-driven insights that enhance trial outcomes while ensuring safety and efficacy. Join us as we dive into complex medical challenges and regulatory landscapes, offering innovative solutions tailored for pharma pioneers. Featuring expertise from industry leaders, each episode is crafted to provide clarity, foster debate, and challenge mainstream perspectives, ensuring you remain at the forefront of clinical trial excellence.
Show more...
Mathematics
Health & Fitness,
Medicine,
Science
RSS
All content for In the Interim... is the property of Berry and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
A podcast on statistical science and clinical trials. Explore the intricacies of Bayesian statistics and adaptive clinical trials. Uncover methods that push beyond conventional paradigms, ushering in data-driven insights that enhance trial outcomes while ensuring safety and efficacy. Join us as we dive into complex medical challenges and regulatory landscapes, offering innovative solutions tailored for pharma pioneers. Featuring expertise from industry leaders, each episode is crafted to provide clarity, foster debate, and challenge mainstream perspectives, ensuring you remain at the forefront of clinical trial excellence.
Show more...
Mathematics
Health & Fitness,
Medicine,
Science
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/64/33/ba/6433ba0f-405d-81e6-bc82-4d4f04775f0a/mza_2622887070788468434.jpg/600x600bb.jpg
The Time Machine
In the Interim...
39 minutes
3 weeks ago
The Time Machine

Dr. Scott Berry and Dr. Kert Viele discuss the origins and implementation of the “time machine” modeling approach, beginning with sports analytics and progressing to adaptive platform clinical trials. The episode focuses on how techniques for comparing athletes across eras translate into methodology for platform trials.

Key Highlights

  • Sports analytics as foundation: Early work of modelling athlete comparisons across eras using bridging methodologies.
  • Platform trial application: The time machine model in I-SPY 2 enabled efficient control allocation through overlapping arms over extended trial periods.
  • Core modeling principles: Additive treatment effect assumptions and the necessity of sufficient temporal overlap for reliable era comparisons.
  • Statistical implementation: Approaches include categorical era adjustment and Bayesian smoothing splines for modeling change over time.
  • Limitations and disease specificity: In conditions with rapid clinical or epidemiologic change, such as COVID-19, non-concurrent controls are avoided due to high risk of era by treatment interaction.
  • Regulatory and methodological distinction: The model leverages within-trial overlapping data collected under a unified protocol, contrasting sharply with external or historical controls.
In the Interim...
A podcast on statistical science and clinical trials. Explore the intricacies of Bayesian statistics and adaptive clinical trials. Uncover methods that push beyond conventional paradigms, ushering in data-driven insights that enhance trial outcomes while ensuring safety and efficacy. Join us as we dive into complex medical challenges and regulatory landscapes, offering innovative solutions tailored for pharma pioneers. Featuring expertise from industry leaders, each episode is crafted to provide clarity, foster debate, and challenge mainstream perspectives, ensuring you remain at the forefront of clinical trial excellence.